Literature DB >> 25583771

Guideline familiarity predicts variation in self-reported use of routine surveillance PET/CT by physicians who treat head and neck cancer.

Benjamin R Roman1, Snehal G Patel2, Marilene B Wang2, Anna M Pou2, F Christopher Holsinger2, David Myssiorek2, David Goldenberg2, Samuel Swisher-McClure2, Alexander Lin2, Jatin P Shah2, Judy A Shea2.   

Abstract

BACKGROUND: Use of routine surveillance testing beyond guideline recommended levels is common in many oncologic disciplines, including head and neck cancer. The impact of guideline familiarity and other physician characteristics on surveillance imaging use are not well understood.
METHODS: A cross-sectional national survey was performed of physicians responsible for surveillance of patients with head and neck squamous cell carcinoma (HNSCC). The primary outcome was self-reported use of routine surveillance PET/CT in asymptomatic patients. A secondary outcome was familiarity with guideline recommendations. Using multivariable regression, the impact of guideline familiarity and other physician characteristics on PET/CT use was examined.
RESULTS: Of the 502 responders, 79% endorsed ever using PET/CT scans for routine surveillance imaging, and 39% were high imaging users (used PET/CT scans on more than half of their asymptomatic patients); 76% were familiar with the NCCN Clinical Practice Guidelines in Oncology for Head and Neck Cancers recommending against routine surveillance PET/CT scans. Although guideline familiarity was associated with being a low imaging user or a never-user, among those who were familiar with guidelines, 31% were nonetheless high imaging users and 73% endorsed ever using PET/CT scans. In multivariable analysis controlling for physician characteristics, guideline familiarity was the strongest predictor of PET/CT use.
CONCLUSIONS: Familiarity with the NCCN Guidelines predicts self-reported routine surveillance PET/CT use among physicians who treat patients with HNSCC. However, given the observed variation and high levels of imaging even among physicians who are familiar with the guidelines, further research should examine the reasons physicians choose to use surveillance PET/CT scans.
Copyright © 2015 by the National Comprehensive Cancer Network.

Entities:  

Mesh:

Year:  2015        PMID: 25583771     DOI: 10.6004/jnccn.2015.0010

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   11.908


  7 in total

1.  Usefulness of surveillance imaging in patients with head and neck cancer who are treated with definitive radiotherapy.

Authors:  Sweet Ping Ng; Courtney Pollard; Joel Berends; Zeina Ayoub; Mona Kamal; Adam S Garden; Houda Bahig; Scott B Cantor; Andrew J Schaefer; Temitayo Ajayi; G Brandon Gunn; Steven J Frank; Heath Skinner; Jack Phan; William H Morrison; Renata Ferrarotto; Jason M Johnson; Abdallah S R Mohamed; Stephen Y Lai; Amy C Hessel; Erich M Sturgis; Randal S Weber; Clifton D Fuller; David I Rosenthal
Journal:  Cancer       Date:  2019-02-12       Impact factor: 6.860

Review 2.  Defining value-driven care in head and neck oncology.

Authors:  Benjamin R Roman; Mahmoud I Awad; Snehal G Patel
Journal:  Curr Oncol Rep       Date:  2015-01       Impact factor: 5.075

3.  Initial Performance of NI-RADS to Predict Residual or Recurrent Head and Neck Squamous Cell Carcinoma.

Authors:  D A Krieger; P A Hudgins; G K Nayak; K L Baugnon; A S Corey; M R Patel; J J Beitler; N F Saba; Y Liu; A H Aiken
Journal:  AJNR Am J Neuroradiol       Date:  2017-03-31       Impact factor: 3.825

4.  Perceived value drives use of routine asymptomatic surveillance PET/CT by physicians who treat head and neck cancer.

Authors:  Benjamin R Roman; Shivangi Lohia; Nandita Mitra; Marilene B Wang; Anna M Pou; F Christopher Holsinger; David Myssiorek; David Goldenberg; David A Asch; Judy A Shea
Journal:  Head Neck       Date:  2020-01-10       Impact factor: 3.147

5.  Evaluation of Optimal Assessment Schedules for Surveillance After Definitive Locoregional Treatment of Locally Advanced Head and Neck Cancer: A Retrospective Cohort Study With Parametric Modeling of Event-Free Survival.

Authors:  Hye In Lee; Jongjin Lee; Joo Ho Lee; Hong-Gyun Wu; Jin Ho Kim; Yongdai Kim; Keun-Yong Eom
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2022-09-29       Impact factor: 8.961

6.  Disparities and guideline adherence for HPV testing among patients with oropharyngeal squamous cell carcinoma, NCDB, and SEER.

Authors:  Solomon Husain; Shivangi Lohia; Valentina Petkov; Timothy Blackwell; Samuel Swisher-McClure; Aviram Mizrachi; Luc G Morris; Marc A Cohen; Richard J Wong; Benjamin R Roman
Journal:  Head Neck       Date:  2021-04-13       Impact factor: 3.821

Review 7.  Follow-Up of Head and Neck Cancer Survivors: Tipping the Balance of Intensity.

Authors:  Petr Szturz; Carl Van Laer; Christian Simon; Dirk Van Gestel; Jean Bourhis; Jan B Vermorken
Journal:  Front Oncol       Date:  2020-05-06       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.